Extreme insulin resistance: Indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus

Current Diabetes Reports

Volumn 11, Issue 2, 2011, Pages 77-82

  Dailey, Alexandria M ^a   Tannock, Lisa R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Hypoglycemia; Insulin efficacy; Insulin resistance; Obesity; Pharmacokinetics; U 500 insulin

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN INFUSION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT WITHDRAWAL; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; PATIENT SATISFACTION; PRESCRIPTION DRUGS; TREATMENT OUTCOME;

EID: 79955820380     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0167-6     Document Type: Review

References (25)

1. Clearinghouse NDI: National Diabetes Statistics. Edited by 2008, p.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, N Engl J Med 1993 329:977-986.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998 352:837-853.
4. Holman RR, Paul SK, Bethel MA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med 2008 359:1577-1589.
5. Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, N Engl J Med 2005 353:2643-2653. (Pubitemid 41817713)
6. Garg R, Johnston V, McNally PG, et al.: U-500 insulin: why, when and how to use in clinical practice, Diabetes/metabolism research and reviews 2007 23:265-268.
7. Ballani P, Tran MT, Navar MD, Davidson MB: Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients, Diabetes Care 2006 29:2504-2505.
8. Dailey AM, Williams S, Taneja D, Tannock LR: Clinical efficacy and patient satisfaction with U-500 insulin use, Diabetes Res Clin Pract 2010 88:259-264.
9. Knee TS, Seidensticker DF, Walton JL, et al.: A novel use of U- 500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series, Endocr Pract 2003 9:181-186.
10. Lane WS, Cochran EK, Jackson JA, et al.: High-dose insulin therapy: is it time for U-500 insulin?, Endocr Pract 2009 15:71-79. This is a useful algorithm for converting patients from U-100 insulin to U-500 insulin by either multiple daily injections or continuous subcutaneous infusion.
11. Company ELa: Humulin R Regular U-500 (Concentrated) Insulin Edited by 2007, p.
12. Jorgensen KH, Hansen AK, Buschard K: Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs, Diabetes Res Clin Pract 2000 50:161-167.
13. Khan M, Lee Y: The pharmacokinetics and pharmacodynamics of regular U500 insulin in healthy non-obese subjects [abstract], Diabetes 2007 56:1294P.
14. Khan M, Sarabu B: The pharmacokinetic and pharmacodynamic properties of regular U500 insulin in healthy obese subjects [abstract], Diabetes 2009 58:2333P.
15. Gagnon-Auger M, du Souich P, Baillargeon JP, et al.: Dosedependent delay of the hypoglycemic effect of short-acting insulin analogues in obese subjects with type 2 diabetes mellitus: a pharmacokinetic and pharmacodynamic study, Diabetes Care 2010
16. Davidson MB, Navar MD, Echeverry D, Duran P: U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients, Diabetes Care 2010 33:281-283. This is a pharmacokinetic study evaluating U-500 insulin in obese insulin-resistant diabetic subjects.
17. Garg SK, Gottlieb PA, Hisatomi ME, et al.: Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine, Diabetes Res Clin Pract 2004 66:49-56.
18. Nayyar V, Lawrence I, Kong MF, et al.: Long-term follow up of patients on U-500 Human Actrapid, Diabetologia 2007 50:
19. Neal JM: Analysis of effectiveness of human U-500 insulin in patients unresponsive to conventional insulin therapy, Endocr Pract 2005 11:305-307.
20. Wafa WS, Khan MI: Use of U-500 regular insulin in type 2 diabetes, Diabetes Care 2006 29:2175-2176. (Pubitemid 44871206)
21. Garg R, Lawrence IG, Akinsola MO, et al.: Improved glycaemic control in severely insulin resistant, insulin-treated diabetic patients with U500 Actrapid over two year follow up [abstract], Diabetologia 2004 47:149.
22. Bulchandani DG, Konrady T, Hamburg MS: Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes, Endocr Pract 2007 13:721-725.
23. Lane WS: Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance, Endocr Pract 2006 12:251-256.
24. Lane WS, Weinrib SL, Rappaport JM, Przestrzelski T: A Prospective Trial of U-500 Insulin Delivered by Omnipod in Patients with Type 2 Diabetes and Severe Insulin Resistance, Endocr Pract 2010 1-30. This is a nice demonstration of improved glycemic control as evaluated by continuous glucose monitoring in subjects receiving U-500 insulin via continuous infusion. This study also demonstrates 12-month durability of glycemic control.
25. Cochran E, Musso C, Gorden P: The use of U-500 in patients with extreme insulin resistance, Diabetes Care 2005 28:1240-1244. (Pubitemid 40616647)